Analyst Downgrades: Valeant Pharmaceuticals Intl Inc, Sabra Health Care REIT Inc, and Yamana Gold Inc.

Analysts downwardly revised their ratings on Valeant Pharmaceuticals Intl Inc (VRX), Sabra Health Care REIT Inc (SBRA), and Yamana Gold Inc. (USA) (AUY)

by Alex Eppstein

Published on Nov 2, 2015 at 9:51 AM

Analysts are weighing in on drugmaker Valeant Pharmaceuticals Intl Inc (NYSE:VRX), real-estate investment trust Sabra Health Care REIT Inc (NASDAQ:SBRA), and precious metal purveyor Yamana Gold Inc. (USA) (NYSE:AUY). Here's a quick roundup of today's bearish brokerage notes on VRX, SBRA, and AUY

  • VRX is up 2.4% out of the gate at $96.02, despite a round of bearish brokerage attention. Specifically, Goldman Sachs slashed its rating to "neutral" from "buy," while Jefferies and Canaccord Genuity reduced their respective price targets to $172 and $170. These developments come ahead of Citron Research's looming update on Valeant Pharmaceuticals Intl Inc, and after days of losses caused by the short seller's initial report. In fact, since the original allegations of "channel stuffing" broke, the security has lost roughly one-third of its value. This morning, though, it should be noted that Citron's Andrew Left said investors shouldn't "expect anything earth-shattering" (subscription required) in the soon-to-be-released update, potentially serving as the equity's upward catalyst. On the sentiment front, additional downgrades and price-target reductions remain a possibility. Nearly 70% of analysts rate VRX a "buy" or better -- with not a single "sell" in sight -- while its consensus 12-month price target sits at $291.47, or roughly triple current levels.

  • One week ahead of the company's third-quarter earnings report, SBRA plummeted to a two-year low of $20.91, and was last seen down 7.2%  at $21.05 in early trading on a bearish note from RBC. Specifically, the firm cut its rating to "underperform" from "sector perform," and its price target to $22 from $26, citing concerns about Sabra Health Care REIT Inc's Forest Park investment. Additional downward revisions could be around the corner, with more than half of covering analysts handing out "buy" or better endorsements, and not a single "sell" rating on the books. Plus, SBRA's consensus 12-month price target of $28.54 stands at a 35.6% premium to its current perch.

  • AUY is down 3.2% at $2.12 -- bringing its year-to-date loss beyond 47% -- thanks to a price-target cut to $2.40 from $2.50 at HSBC. This is probably encouraging to option traders, who have been upping the bearish ante in recent weeks. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Yamana Gold Inc. has racked up a 10-day put/call volume ratio of 0.32 -- higher than 83% of comparable readings from the past year. In other words, traders have been buying to open puts over calls at a faster-than-usual clip of late.
Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.
Work-From-Home Shift Draws Analysts to Slack Stock
Several analysts are issuing bull notes to Slack stock today
Google Postpones Android Reveal, "Now is Not the Time to Celebrate"
"Now is not the time to celebrate," Google said in a message on its website
Huge New Legal Marijuana Market Has Shortage Crisis
250 million Europeans have access to medical marijuana. There's already a shortage....